Objective: In this study, we aimed to assess the relative efficacy and safety of intravenous (IV) or subcutaneous (SC) belimumab compared with those of placebo in patients with active systemic lupus erythematosus (SLE). Methods: We performed a Bayesian network meta-analysis to combine the direct and indirect evidence from randomized controlled trials (RCTs) examining the efficacy and safety of belimumab 1 mg/kg and 10 mg/kg IV administration, and belimumab 200 mg SC injection, and placebo in patients with active SLE despite having received standard therapy. Results: Five RCTs (3460 patients) met the inclusion criteria. The SLE Responder Index (SRI) response rate at week 52 was significantly higher in the belimumab 10 mg/kg group than in the placebo group (OR 2.63, 95% CrI 2.14-3.23). Similarly, the SRI response rates were significantly higher in the belimumab 1 mg/kg, and belimumab 200 mg SC groups than in the placebo group (OR 2.42, 95% CrI 1.90-3.09; OR 1.71, 95% CrI 1.27-2.29). Ranking probability based on surface under the cumulative ranking curve (SUCRA) indicated that belimumab 10 mg/kg had the highest probability of being the best treatment for achieving the SRI response (SUCRA ¼ 0.9174), followed by belimumab 1 mg/kg (SUCRA ¼ 0.7338), belimumab 200 mg SC (SUCRA ¼ 0.3487), and placebo (SUCRA ¼ 0.0000). However, a sensitivity test by omitting one outlier study showing low SRI response rate compared with the other three studies (11% vs. 33%, 40%, 48%) showed that belimumab 200 mg SC and belimumab 10 mg/kg had the highest probability of being the best treatment for achieving the SRI response (SUCRA ¼ 0.7903, SUCRA ¼ 0.7456), followed by belimumab 1 mg/kg, and placebo. The number of serious adverse events (SAEs) did not differ significantly among the four treatment options. Conclusions: Belimumab at 1 and 10 mg/kg IV and belimumab 200 mg SC in combination with standard therapy was an efficacious intervention for active SLE, and was not associated with a significant risk of SAEs. Lupus (2018) 27, 112-119.
Introduction
Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease that disturbs the immune system by increasing the production of multiple autoantibodies by stimulated B cells under the dysregulation of T and B cells, 1 thereby resulting in tissue damage by either binding directly to self-antigens or inducing inflammation through the tissue deposition of immune complexes.
2 B-cell hyperactivity causes an increased response to many antigens, both self and foreign.
2 B lymphocyte stimulator (BLyS, a B-cell-activating factor) is a member of the TNF ligand superfamily, as well as functioning as a B-cell stimulator and regulator. 3 BLyS binds to the BLyS receptor, which is found mainly on B cells, plasma cells, and some subsets of T cells, and is the receptor through which BLyS predominantly mediates its agonist effects on B cells. 4 It plays an essential role in B-cell maturation, survival, and function by inhibiting B-cell apoptosis, as well as in immunoglobulin isotype switching 3 by stimulating the differentiation of B cells into immunoglobulin-producing plasma cells. BLyS levels were significantly higher in patients with SLE, and higher levels correlated with increased SLE disease activity and elevated anti-double stranded (ds) DNA. BLyS transgenic mice develop high titers of anti-DNA antibodies, hypergammaglobulinemia, and glomerulonephritis, which is similar to SLE in humans. 5 Furthermore, selective BLyS blocking has been shown to decrease symptoms of SLE in mouse models. 6 Current therapies such as corticosteroids, hydroxychloroquine, and immunosuppressive drugs have improved the outcomes of patients with SLE, but there is a significant unmet need for safe and more effective treatments. 7 Belimumab is a human immunoglobulin (Ig) G1-monoclonal antibody that binds to soluble human BLyS and inhibits the survival of autoreactive B cells by preventing the B-cell survival factor, BLyS, from binding to its receptors on B cells. 8 It selectively reduces anti-dsDNA antibody titers and the number of subsets of CD20þ B lymphocytes and short-lived plasma cells in patients with SLE. 9 Several clinical trials have been carried out to evaluate the efficacy and safety of belimumab in patients with active SLE who had an incomplete response to standard therapy, [10] [11] [12] [13] and previous meta-analyses showed that belimumab was effective in active SLE patients and had a manageable safety profile. 14, 15 Nevertheless, the comparative efficacy and safety of belimumab at different dosages in combination with standard therapy remains unclear because of the limited data available from multiple comparison analyses. Therefore, by using a network meta-analysis, 16 in the present study we aimed to compare the efficacy and safety of belimumab 1 and 10 mg/kg intravenous (IV) administration, and belimumab 200 mg (SC) subcutaneous injection with those of placebo in patients with active SLE despite having received standard therapy.
Methods

Identification of eligible studies and data extraction
We performed an exhaustive search for studies that examined the efficacy and safety of belimumab in patients with active SLE. A literature search was performed using MEDLINE, EMBASE, and the Cochrane Controlled Trials Register to identify available articles (up to January 2017).
The following key words and subject terms were used in the search: ''lupus,'' ''systemic lupus erythematosus,'' and ''belimumab.'' All article references were reviewed to identify additional studies that were not included in the electronic databases. Randomized controlled trials (RCTs) were included if they met the following criteria: (1) the study compared belimumab with placebo in the treatment of patients with active SLE (score !4 at screening on SELENA-SLEDAI) despite having received standard therapy, (2) the study provided end points for the clinical efficacy and safety of belimumab, and (3) the study included patients diagnosed with SLE based on the American College of Rheumatology criteria for SLE. No language or race/ethnicity restrictions were applied. The exclusion criteria for a study were as follows: (1) inclusion of duplicate data, and (2) lack of adequate data for inclusion. The efficacy outcome was the SLE Responder Index (SRI) response rate at week 52 (an SRI response was defined as a >4-point reduction in SELENA-SLEDAI score, no new British Isles Lupus Assessment Group [BILAG] A organ domain scores and no more than one new BILAG B score, and no worsening in Physician's Global Assessment score versus baseline). 17 The efficacy outcome was created by evidence-based RCTs as a primary end point with a clinically meaningful change in SLE trials. 17 The safety outcome was the number of patients that experienced serious adverse events (SAEs) until week 52. The following information was extracted from each study: first author, year of publication, country in which the study was conducted, belimumab dose, number of patients treated with belimumab and placebo, clinical features, and safety and efficacy outcomes at 52 weeks. We quantified the methodological qualities of the four studies using Jadad scores. 18 The Jadad scale assesses random assignment, double-blinding, and patient withdrawal and dropout rates. Jadad scores range from zero to five. Quality was classified as high (score of 3-5) or low (score of 0-2). We conducted a network meta-analysis in accordance with the guidelines provided by the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement. 19 
Evaluation of statistical associations for network meta-analysis
The efficacy and safety of belimumab 1 mg/kg, belimumab 10 mg/kg, belimumab 200 mg SC, and placebo for SLE therapy were in the order according to the probability of being ranked as the best-performing agent. A fixed-effects model was used because of homogenous populations, and a Bayesian network meta-analysis was conducted using NetMetaXL 20 and WinBUGS statistical analysis program version 1.4.3 (MRC Biostatistics Unit, Institute of Public Health, Cambridge, UK). A Bayesian analysis needs two ingredients: (1) prior distributions for the unknown parameters and (2) a likelihood function derived from a model that specifies the relation between the unknown parameters and the observed data. 20 A prior distribution of a parameter represents the uncertainty about the parameter before the current data are examined. 20 The prior chosen was ''vague'' in this analysis. ''Vague'' is considered as ''let the data drive the analysis''. 20 The Markov Chain Monte Carlo method was used to obtain the pooled effect sizes. 21 All chains were run with 10,000 burn-in iterations followed by 10,000 monitoring iterations. The information on relative effects was converted to a probability that a treatment was best, second best, and so on, with the ranking of each treatment (called the surface under the cumulative ranking curve, or SUCRA 22 ) expressed as a percentage between 100% and 0% when a treatment is certain to be the best and the worst, respectively. The summary estimates were presented in league tables by ranking the treatments in order of the most pronounced impact on the outcome under consideration based on SUCRA. 22 We reported the pairwise OR and 95% credible interval (CrI) adjusted for multiplearm trials. Pooled results were considered statistically significant if the 95% CrI did not contain the value 1.
Test for inconsistency and sensitivity analysis
Inconsistency refers to the extent of disagreement between direct and indirect evidence. 23 Assessment of inconsistency is important for conducting a network meta-analysis. 24 We plotted the posterior mean deviance of the individual data points in the inconsistency model against their posterior mean deviance in the consistency model to assess network inconsistency between direct and indirect estimates in each loop. 25 We performed a sensitivity test by eliminating one outlier study.
Results
Studies included in the meta-analysis
Using an electronic or manual search, in which 678 studies were excluded for being duplicate or irrelevant publications, we identified 1210 studies relevant to our analysis. Six studies were selected for a full-text review based on the title and abstract details of the related publication. Two of the six studies contained duplicate data, and were therefore excluded. 26, 27 Thus, five RCTs including 3460 patients (1465 efficacy-related events and 562 safety-related events) met the inclusion criteria [10] [11] [12] [13] 28 (Table 1) . Four of the RCTs provided the data regarding SRI at 52 weeks, 10, 11, 13, 28 and all five provided the data on SAE at 52 weeks. [10] [11] [12] [13] 28 Four pairwise comparisons were performed, which comprised 11 direct comparisons (three studies of belimumab 1 mg/kg vs. placebo, four studies of belimumab 10 mg/kg vs. placebo, one study of belimumab 200 mg SC vs. placebo, and three studies of belimumab 10 mg/kg vs. belimumab 1 mg/kg) and four interventions, including three studies of belimumab 1 mg/kg, four studies of belimumab 10 mg/ kg/kg, one study of belimumab 200 mg SC, and four studies of placebo for the network meta-analysis. The studies by Zhang and Wallace and Stohl et al. 12, 13, 28 received lower Jadad scores than the ones by Navarra and Furie et al. 10 ,11 because they did not provide data on the appropriate method on randomization and blinding. However, Jadad scores of all of the studies ranged from 3 to 5, indicating high study quality (Table 1 ). All patients received standard therapy, and relevant features of the studies included in the meta-analysis are provided in Table 1 .
Network meta-analysis of the efficacy of belimumab 1 mg/kg, belimumab 10 mg/kg, belimumab 200 mg SC, and placebo in RCTs
We considered the number of SRI response rates as the efficacy outcome. Belimumab 10 mg/kg is listed in the top left of the diagonal of the league table (Table 2) because it was associated with the most favorable SUCRA for the SRI response rate, while placebo is listed in the bottom right of the diagonal of the league table because it was associated with the least favorable results. For interpretation purposes, the results are read from top to bottom and left to right. The SRI response rate was significantly higher in the belimumab 10 mg/kg group than in the placebo group (OR 2.63, 95% CrI 2.14-3.23) (Table 2, Figure 1) . Similarly, the SRI response rates were significantly higher in the belimumab 1 mg/kg, and belimumab 200 mg SC groups than in the placebo group (OR 2.42, 95% CrI 1.90-3.09; OR 1.71, 95% CrI 1.27-2.29) (Table 2, Figure 1 ). Belimumab 10 mg/kg tended to be more efficacious than belimumab 1 mg/kg (OR 1.09, 95% CrI 0.87-1.36), and it was more efficacious than belimumab 200 mg SC (OR 1.54, 95% CrI 1.07-2.21) (Table 2, Figure 1 ). Ranking probability based on SUCRA indicated that belimumab 10 mg/kg had the highest probability of being the best treatment for achieving the SRI response (SUCRA ¼ 0.9174), followed by belimumab 1 mg/kg (SUCRA ¼ 0.7338), belimumab 200 mg SC (SUCRA ¼ 0.3487), and placebo (SUCRA ¼ 0.0000) ( Table 3 ). There was one outlier study with respect to SRI. 10 The study showed low SRI response rate compared with those in other studies (11% vs. 33%, 40%, 48%). 10 Therefore, we performed a sensitivity test by eliminating one outlier study with low SRI response rate to reduce the bias of the heterogeneity. The sensitivity test showed that belimumab 200 mg SC and belimumab 10 mg/kg had the highest probability of being the best treatment for achieving the SRI response (SUCRA ¼ 0.7903, SUCRA ¼ 0.7456), followed by belimumab 1 mg/kg (SUCRA ¼ 0.4589), and placebo (SUCRA ¼ 0.0052) ( Tables 2 and 3) .
Network meta-analysis of the safety of belimumab 1 mg/kg, belimumab 10 mg/kg, belimumab 200 mg SC, and placebo in RCTs
We considered the number of SAEs as the safety outcome. The interventions were not in the same order in efficacy and safety sections of league tables, because their SUCRAs were different between efficacy and safety. Ranking probability (Table 3) . However, the number of SAEs did not differ significantly among the four treatment options ( Table 2 , Figure 1 ).
Inconsistency and sensitivity analysis
Inconsistency plots assessing network inconsistencies between direct and indirect estimates showed a low possibility that inconsistencies Figure 1 Bayesian network meta-analysis results of randomized controlled studies on the relative efficacy and safety of belimumab 1 mg/kg, belimumab 10 mg/kg, belimumab 200 mg SC and placebo, based on the SLE Responder Index (SRI) (for efficacy) and number of serious adverse events (for safety).
significantly affect the network meta-analysis results (Figure 2 ).
Discussion
We conducted a network meta-analysis to compare the relative efficacy and safety of different belimumab doses with those of placebo in patients with active SLE despite having received standard therapy. This analysis approach was chosen because it enables an indirect comparison of multiple treatments, which are either lacking in or have insufficient direct head-to-head comparisons. Our network meta-analysis assessed the SRI response rate and the number of SAEs in the three differently treated active SLE patient groups. We chose SRI index as an efficacy outcome in this analysis, because it optimized the strengths of the disease activity scales. SRI reflects improvement in disease activity by using a global scoring system while simultaneously requiring that there be no worsening of the disease in any organ system or by physician judgment. 17 We then generated a rank order of efficacy and safety of the three treatment paradigms for patients with active SLE. Our network metaanalysis suggests that belimumab 10 mg/kg has the highest efficacy in the treatment of active SLE, followed by belimumab 1 mg/kg, belimumab 200 mg SC, and placebo. Statistically significant differences between the placebo group and belimumab groups were observed with respect to the efficacy end point (SRI). Belimumab 10 mg/kg showed a numerically higher efficacy than belimumab 1 mg/ kg did. However, no statistically significant difference in SRI response rates was found between the belimumab 10 mg/kg and 1 mg/kg doses. Sensitivity test by eliminating one study with low SRI response rate 10 indicated that belimumab 200 mg SC and belimumab 10 mg/kg had the highest probability of being the best treatment for achieving the SRI response. With respect to safety, no significant difference was observed in the number of SAEs among the three interventions, suggesting a comparable safety profile among the two belimumab dosages used, belimumab 200 mg SC, and the placebo group. Belimumab in combination with standard therapy was effective in the treatment of patients with active SLE, and showed an acceptable safety profile. Use of network meta-analysis has increased, but this is the first network meta-analysis that evaluated comprehensive and simultaneous assessment of belimumab for SLE. Our results, which combined evidence from both direct and indirect comparisons for evaluating the relative efficacy and safety of belimumab, are consistent with those of previous meta-analyses.
BLyS is a 250 amino acid protein produced and secreted by monocytes, activated T cells, and dendritic cells. 29 BLyS plays an important role in the stimulation, proliferation, survival, and maturation of B cells into plasma cells, which produce immunoglobulins. 3 Overexpression of BLyS promotes survival of B cells, whereas inhibition of BLyS results in autoreactive B-cell apoptosis. Mice deficient in BLyS lack mature B cells and are immunodeficient, whereas mice that overexpress BLyS demonstrated high immunoglobulin levels (including high levels of autoantibodies) and SLE-like disease with immune complex glomerulonephritis. 5 In addition, selective blockade of BLyS decreased symptoms of SLE in mouse models. 6 BLyS levels are elevated in SLE, and higher BLyS levels correlate with increased SLE disease activity. These lines of evidence suggest that increased BLyS levels may play a major role in the pathogenesis of SLE. 30 Belimumab is the only biologic approved by the Food and Drug Administration (FDA) for SLE, providing a new option for the management of SLE in patients with active, autoantibody-positive SLE who are receiving standard therapy, including corticosteroids, antimalarial, immunosuppressive, and nonsteroidal anti-inflammatory drugs. 31 A 10 mg/kg dosage of belimumab was approved and recommended by the FDA, although belimumab 1 mg/kg was also associated with significantly more benefits than placebo in patients with SLE.
Our results should be interpreted with caution because of several shortcomings of our study. First, the follow-up time point was relatively short (52 weeks). The follow-up duration was too short for an evaluation of the long-term effects. Longer comparative studies in the future are warranted. Second, there was heterogeneity in the design and patient characteristics of the included trials; thus, there is a possibility that these differences across studies affected the results of this network meta-analysis. Third, we did not comprehensively address the efficacy and safety outcomes of belimumab in SLE. We only focused on the effectiveness based on the SRI response and on the safety according to the number of SAEs, without assessing various outcomes. Nevertheless, this meta-analysis also has a strength. The number of patients with SLE from the individual studies ranged from 338 to 865, but this pooled analysis included 3460 patients. In contrast with the individual studies, we were able to provide more accurate data by increasing the statistical power and resolution through pooling the results of independent analyses.
In conclusion, by using a Bayesian network meta-analysis involving five RCTs comparing three different pharmacological interventions, we found that belimumab at dosages of 1 mg/kg and 10 mg/kg and belimumab 200 mg SC in combination with standard therapy was an efficacious intervention for patients with active SLE, and was not associated with a significant risk of SAEs. Nevertheless, long-term studies are needed to determine the relative efficacy and safety of belimumab in a large number of patients with active SLE.
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